Get started
Author

Mehmet Fatih Ozbay

Observed names: M. Fatih Ozbay, Mehmet Fatih ÖZBAY, Mehmet Fatih Özbay
Institution: Akdeniz University
ORCID: 0000-0002-3883-4364
Observed ORCID: 0000-0002-3883-4364
OpenAlex ID: A5081240946
Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography
2017 · Harun Arslan, Mehmet Fatih Özbay, et al. · Radiology and Oncology · 33
PDF
Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey
2014 · Alper Can, Erkan Dogan, et al. · Asian Pacific Journal of Cancer Prevention · 30
PDF
Plasma Concentrations of Some Trace Element and Heavy Metals in Patients with Metastatic Colon Cancer
2013 · Ozgur Emre, Halit Demir, et al. · Journal of Cancer Therapy · 26
PDF
Evaluation of Lipid Peroxidation and Some Antioxidant Activities in Patients with Primary and Metastatic Liver Cancer
2014 · Ayse Arslan, Halit Demir, et al. · Journal of Cancer Therapy · 17
PDF
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes
2024 · Mehmet Fatih Ozbay, Hakan Harputluoglu, et al. · Cancers · 10
Oxidative stress in patients with thyroidectomy and thyroparathyroidectomy under replacement therapy
2014 · Murat Kaçmaz, Murat Atmaca, et al. · Endocrine · 10
Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey
2013 · Ummugul Uyeturk, Ali Murat Tatli, et al. · Asian Pacific Journal of Cancer Prevention · 9
PDF
The ascendancy of eosinophil counts in non-small cell lung cancer: a potential marker for predicting response and survival under nivolumab treatment
2024 · Mehmet Fatih Ozbay, Aysegul Merc Cetinkaya, et al. · American Journal of Cancer Research · 5
PDF
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
2022 · Emre Yekedüz, Mehmet Fatih Özbay, et al. · European Journal of Clinical Pharmacology · 5
PDF
Ocular findings in Sheehan’s syndrome
2015 · Murat Atmaca, Esra Kızıldağ, et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 5
Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer
2025 · Yusuf Ilhan, Onur Yazdan Balcik, et al. · World Journal of Gastrointestinal Oncology · 4
PDF
Functioning Adrenocortical Oncocytic Carsinoma: A Case Report
2013 · Murat Atmaca, Saliha Yıldız, et al. · Open Journal of Endocrine and Metabolic Diseases · 2
PDF
Corneal Epithelial Alterations Associated With Cyclin-Dependent Kinase 4/6 Inhibitor Therapy in Hormone Receptor–Positive Breast Cancer
2026 · Esra Kızıldag Ozbay, Banu Ozturk, et al. · American Journal of Ophthalmology · 1
Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
2024 · Mehmet Fatih Ozbay · Frontiers in Immunology · 1
PDF
Effects of Endogen Erythropoietin on Parathormone Secretion
2021 · Edip Gönüllü, Sezai Özkan, et al. · Forbes Journal of Medicine · 1
PDF
Association of Acromegaly and Multiple Myeloma: A Case Report
2013 · Murat Atmaca, Saliha Yıldız, et al. · Endocrinology research and practice. · 1
Baseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death During PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
2026 · Mehmet Fatih Ozbay, Mehmet Hunur, et al. · Current Oncology
Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer
2026 · Mehmet Fatih Ozbay, Fikret Atlım, et al. · Cancer Chemotherapy and Pharmacology
Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
2024 · Mehmet Fatih Ozbay, Yusuf Ilhan · European Journal of Cancer
Clinical Significance of Pazopanib-Related Macrocytosis in Metastatic Renal Cell Carcinoma and Sarcomas
2023 · Yusuf İLHAN, Mehmet Fatih ÖZBAY, et al. · Akdeniz Medical Journal
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
2022 · Emre Yekedüz, Mehmet Fatih Özbay, et al. · Research Square
PDF
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
2022 · Emre Yekedüz, Mehmet Fatih Özbay, et al. · Research Square
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study.
2022 · Emre Yekeduz, Mehmet Fatih Ozbay, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 160
H-index: 7
I10-index: 6
Year
Topic
Type